Overview of the European and North American studies on HPV testing in primary cervical cancer screening.
Jack Cuzick,Christine Clavel,Karl Ulrich Petry,Chris J.L.M. Meijer,Heike Hoyer,Sam Ratnam,Anne Szarewski,Philippe Birembaut,Shalini L Kulasingam,Peter Sasieni,Thomas Iftner +10 more
TLDR
The results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive, with large demonstration projects needed to fully evaluate this strategy.Abstract:
Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages <35, 35–49 and 50+. The age-specific prevalence of high risk HPV (hr-HPV) was also analysed. HPV testing was substantially more sensitive in detecting CIN2+ than cytology (96.1% vs. 53.0%) but less specific (90.7% vs. 96.3%). The sensitivity of HPV testing was similar in all studies carried out in different areas of Europe and North America, whereas the sensitivity of cytology was highly variable. HPV sensitivity was uniformly high at all ages, whereas the sensitivity of cytology was substantially better in women over the age of 50 than in younger women (79.3% vs. 59.6%). The specificity of both tests increased with age. Positivity rates for HPV testing in women without high-grade CIN were region dependent. These results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive. Large demonstration projects are needed to fully evaluate this strategy. © 2006 Wiley-Liss, Inc.read more
Citations
More filters
Journal ArticleDOI
Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes.
Viola M.J. Verhoef,Folkert J. van Kemenade,Lawrence Rozendaal,Daniëlle A.M. Heideman,Remko P. Bosgraaf,Albertus T. Hesselink,Willem J. G. Melchers,Leon F.A.G. Massuger,Ruud L.M. Bekkers,Renske D.M. Steenbergen,Johannes Berkhof,Peter J.F. Snijders,Chris J.L.M. Meijer +12 more
TL;DR: Cytology and bi-marker CADM1/MAL-methylation analysis perform complementary for CIN2+/CIN3+ detection when used as triage tool on cervical scrapes of HPV positive women, and seems to reduce the risk of missing cervical cancers and advanced high-grade lesions.
Journal ArticleDOI
A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes.
TL;DR: The performance of both assays was similar for ThinPrep specimens, but the Roche cobas test demonstrated higher sensitivity with Sure path specimens, while the Hybrid Capture 2 test showed good agreement and excellent specificity.
Journal ArticleDOI
Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology
Longwen Chen,Bin Yang +1 more
TL;DR: Assessment of the potential role of reflex HPV testing in guiding subsequent colposcopy‐directed cervical biopsy/curettage in a large tertiary care hospital setting is assessed.
Journal ArticleDOI
Evaluation of the Impact of Human Papillomavirus DNA Self-sampling on the Uptake of Cervical Cancer Screening.
Eliza L.Y. Wong,Paul K.S. Chan,Josette S.Y. Chor,Annie Wai Ling Cheung,Fenwei Huang,Samuel Y. S. Wong +5 more
TL;DR: It is estimated that the introduction of HPV DNA self-sampling could increase the future rate of uptake of cervical cancer screening by 6.5% and would entail lower costs.
Journal ArticleDOI
Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening
Kimon Chatzistamatiou,Theodoros Moysiadis,Viktoria Moschaki,Nikolaos Panteleris,Theodoros Agorastos +4 more
TL;DR: HPHPV testing with HPV 16/18 genotyping, as a triage method to colposcopy, reflects the best equilibrium between screening effectiveness and harm, and algorithms based on cytology as initial screening method, on co-testing or HPV primary without genotypesing, and on HPV primary with genotyped but without cytology triage, are not supported according to the present analysis.
References
More filters
Journal ArticleDOI
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Jan M. M. Walboomers,M. V. Jacobs,M. M. Manos,Franz X. Bosch,J. A. Kummer,Keerti V. Shah,Peter J.F. Snijders,Julian Peto,Chris J.L.M. Meijer,Nubia Muñoz +9 more
TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Journal ArticleDOI
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study
Ciaran B J Woodman,Stuart Collins,Heather Winter,Andrew Bailey,John Ellis,Pat Prior,Marie Yates,Terry P. Rollason,Lawrence S. Young +8 more
TL;DR: The findings suggest that attempts to exploit the association between cervical neoplasia and HPV infection to improve effectiveness of cervical screening programmes might be undermined by the limited inferences that can be drawn from the characterisation of a woman's HPV status at a single point in time, and the short lead time gained by its detection.
Journal ArticleDOI
Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study
M A E Nobbenhuis,Jan M. M. Walboomers,Theo J.M. Helmerhorst,Lawrence Rozendaal,A. J. Remmink,Elle K.J. Risse,Hans C. van der Linden,Feja J. Voorhorst,Peter Kenemans,Chris J.L.M. Meijer +9 more
TL;DR: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of cervical intraepithelial neoplasia CIN 3, and all women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dysKaryosis ought to be referred only after a second positive test for high- risk human papillsomav virus at 6 months.
Journal ArticleDOI
Trends in mortality from cervical cancer in the nordic countries: association with organised screening programmes
TL;DR: Investigation of time trends in mortality from cervical cancer in Denmark, Finland, Iceland, Norway, and Sweden since the early 1950s supports the conclusion that organised screening programmes have had a major impact on the reduction in mortality in the Nordic countries.
Journal ArticleDOI
Management of women who test positive for high-risk types of human papillomavirus: The HART study
Jack Cuzick,Anne Szarewski,Heather Cubie,G Hulman,Henry C Kitchener,David Luesley,Euphemia McGoogan,Usha Menon,George Terry,Robert Edwards,Claire Brooks,Mina Desai,C Gie,Linda Lee Ho,Ian Jacobs,C Pickles,Peter Sasieni +16 more
TL;DR: Comparison of the detection rate and positive predictive values of HPV assay with cytology and the best management strategy for HPV-positive women found HPV testing was more sensitive than borderline or worse cytology but less specific for detecting CIN2+.
Related Papers (5)
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
HPV screening for cervical cancer in rural India.
Rengaswamy Sankaranarayanan,Bhagwan M. Nene,Surendra S Shastri,Kasturi Jayant,Richard Muwonge,Atul Budukh,Sanjay Hingmire,Sylla G. Malvi,Ranjit Thorat,Ashok Kothari,Roshan F. Chinoy,Rohini Kelkar,Shubhada Kane,Sangeetha Desai,Vijay R Keskar,Raghevendra Rajeshwarkar,Nandkumar S Panse,Ketayun A. Dinshaw +17 more